Outcome Measures for Clinical Trials with Children with Fragile X Syndrome


Dr. Mattison welcomed the meeting participants and briefly reviewed the history of BPCA and fragile X syndrome (FXS). OPPB was created to (1) identify issues in pediatric and obstetric pharmacology and (2) promote and coordinate research, clinical trials, and drug development activities to improve the safety and efficacy of drugs to treat disease during… (More)


  • Presentations referencing similar topics